Extended Lymphadenectomy Does Not Improve DFS or OS Among Patients with Localised Muscle Invasive Bladder Cancer By Ogkologos - November 4, 2024 1864 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SWOG S1011 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Surgeons Use Tissue From Cancer Survivor’s Love Handles For Rare Type... February 27, 2020 A Positive Trend in OS Improvement Favours Atezolizumab Compared to Best... August 11, 2023 Addressing Common Concerns Around Taking Opioids for Cancer-Related Pain: An Expert... July 5, 2023 Her Cancer Surgery Was Postponed Due To The COVID-19 Pandemic —... July 7, 2020 Load more HOT NEWS Ethnic Diversity and Disparities in Access to Genetic Testing Impact Prostate... Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients... Patient Guide on Bone Health in Cancer Now Available Also in French Ground-breaking trial pilots new tests to detect lung cancer earlier
